Iris.ai vs Causaly (2026)

Iris.ai

by Iris.ai

Causaly

by Causaly

Pros

• ✓Named enterprise adoption across Fortune 500 and government organizations: Mercedes-Benz, ArcelorMittal, USDA, Max Planck Gesellschaft, Springer Nature, and the NATO Communications and Information Agency appear on the official vendor homepage, providing procurement validation that is rare in the regulated enterprise AI infrastructure category.
• ✓Three-product architecture covers the full data-to-AI lifecycle: Axion handles data preparation into AI-ready intelligence, Neuralith powers the enterprise knowledge graph engine, and RSpace delivers precision R&D intelligence. That end-to-end coverage is something fragmented stacks, which require separate vendors for data preparation and AI agent deployment, cannot match.
• ✓A ten-year track record from 2015 through multiple product pivots demonstrates operational maturity. The evolution from academic research AI through scientific language models to Agentic RAG-as-a-Service shows sustained development velocity and enterprise customer retention that AI challengers founded after 2020 cannot replicate.

Limitations

• ⚠No public independent review trail creates procurement friction: the G2 listing was removed in 2026, Trustpilot returns 404, and no Capterra presence exists, so third-party validation outside the vendor homepage logos is difficult. Tools such as Elicit ($49/mo billed annually) and SciSpace ($12/mo billed annually) offer G2-verified reviews for procurement teams that require independent evidence.
• ⚠Named integration depth is not published: the Agentic RAG positioning implies broad enterprise data connectivity, but specific native integrations with SAP, Salesforce, Veeva Vault, SharePoint, PubMed, or Scopus are not confirmed, requiring sales-led scoping before integration depth can be evaluated.
• ⚠Enterprise-only entry with no self-serve evaluation path excludes individual researchers, academic teams, and smaller organizations: the platform requires sales-led engagement, custom data engineering, and sustained implementation investment with no trial access, while Elicit ($49/mo billed annually) and SciSpace ($12/mo billed annually) serve research use cases at a fraction of the cost.

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases: target identification, drug repositioning, mechanism of action investigation, and safety assessment. Outputs carry traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• ⚠Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• ⚠Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• ⚠Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/mo) or ChatGPT Deep Research ($20/mo) substantially more cost-effective outside pharma R&D workflows.